Merck & Co., Inc. is closing down the Keytruda (pembrolizumab) and vibostolimab coformulation arm of a Phase III melanoma trial after an analysis showed a higher dropout rate compared with the Keytruda-only arm due to adverse events, chalking up another loss for anti-PD-1/TIGIT combinations.
Merck Hits Brakes On Anti-PD-1/TIGIT Study In Adjuvant Melanoma
Industry-wide, the combination of PD-1/PD-L1 inhibitors with TIGIT inhibitors has produced a mixed bag in terms of results.
